Rifabutin Use in Staphylococcus Biofilm Infections: A Case Series

Doub, James B.; Heil, Emily L.; Ntem‐Mensah, Afua Duker; Neeley, Renaldo; Ching, Patrick R

doi:10.3390/antibiotics9060326

Cited by 11 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the second real-world case series assessing outcomes associated with use of rifabutin for staphylococcal biofilm infections. Our findings are similar to those described by Doub et al, who noted no infection recurrence among 10 patients who received rifabutin in place of rifampin for prosthetic joint infections due to drug-drug interaction concerns ( 11 ). Rifabutin was well tolerated without side effects in their study.…”

Section: Discussionsupporting

confidence: 92%

A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections

et al. 2022

View full text Add to dashboard Cite

This work evaluates real-world data and clinical outcomes when rifabutin is used in place of rifampin for adjunctive management of staphylococcal hardware-associated infections. This is the second case study looking at this specific use of rifabutin, signifying the current lack of clinical data in this area. Assessing use of rifabutin in this capacity is clinically important given its lower propensity for drug interactions compared to rifampin.

show abstract

Section: Discussionsupporting

confidence: 92%

A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This data attests the potent antimicrobial activity of RFB, in the free form, against S. aureus biofilms, in comparison with the antibiotics clinically used. Indeed, the comparable activity of RFB against planktonic and biofilm of Staphylococcus species was recently described in a case study by Doub J. et al [ 46 ], in which RFB was used instead of rifampin for the treatment of 10 patients with confirmed staphylococcal biofilm infections, further supporting the potential of this antibiotic against S. aureus biofilms associated infections [ 46 ]. Despite the promising therapeutic efficacy of RFB in vitro, high antibiotic doses are necessary to be administered in vivo to achieve inhibitory concentrations at the infected sites, which could lead to systemic toxicity and development of resistant strains.…”

Section: Resultsmentioning

confidence: 71%

“…Among the rifamycin class of antibiotics, rifampicin is the most commonly used, although with severe adverse side effects due to gastrointestinal intolerance or drug-drug interactions. As such, other rifamycins, such as RFB are currently being evaluated as a possible anti-biofilm therapy due to their favorable toxicity and drug interaction behavior [ 26 , 46 ]. Aiming to choose the antibiotic with higher antimicrobial activity against planktonic and biofilm MSSA strain, susceptibility tests were performed for the three selected antibiotics RFB, LEV and VCM ( Figure 1 and Supplementary Material Table S1 [ 47 , 48 , 49 , 50 , 51 , 52 ]).…”

Section: Resultsmentioning

confidence: 99%

Liposomes as a Nanoplatform to Improve the Delivery of Antibiotics into Staphylococcus aureus Biofilms

et al. 2021

View full text Add to dashboard Cite

Staphylococcus aureus biofilm-associated infections are a major public health concern. Current therapies are hampered by reduced penetration of antibiotics through biofilm and low accumulation levels at infected sites, requiring prolonged usage. To overcome these, repurposing antibiotics in combination with nanotechnological platforms is one of the most appealing fast-track and cost-effective approaches. In the present work, we assessed the potential therapeutic benefit of three antibiotics, vancomycin, levofloxacin and rifabutin (RFB), through their incorporation in liposomes. Free RFB displayed the utmost antibacterial effect with MIC and MBIC50 below 0.006 µg/mL towards a methicillin susceptible S. aureus (MSSA). RFB was selected for further in vitro studies and the influence of different lipid compositions on bacterial biofilm interactions was evaluated. Although positively charged RFB liposomes displayed the highest interaction with MSSA biofilms, RFB incorporated in negatively charged liposomes displayed lower MBIC50 values in comparison to the antibiotic in the free form. Preliminary safety assessment on all RFB formulations towards osteoblast and fibroblast cell lines demonstrated that a reduction on cell viability was only observed for the positively charged liposomes. Overall, negatively charged RFB liposomes are a promising approach against biofilm S. aureus infections and further in vivo studies should be performed.

show abstract

“…Based on experimental data, the antibiofilm effect seems to be a class effect of all rifamycin derivatives [26,49,50]. First clinical data suggest that rifabutin is a valuable alternative to rifampin with less adverse events and less drug-drug interactions [51].…”

Section: Role Of Rifampin In Clinical Studies Involving Orthopedic Immentioning

confidence: 99%

Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?

2021

View full text Add to dashboard Cite

Rifampin is a potent antibiotic against staphylococcal implant-associated infections. In the absence of implants, current data suggest against the use of rifampin combinations. In the past decades, abundant preclinical and clinical evidence has accumulated supporting its role in biofilm-related infections.In the present article, experimental data from animal models of foreign-body infections and clinical trials are reviewed. The risk for emergence of rifampin resistance and multiple drug interactions are emphasized. A recent randomized controlled trial (RCT) showing no beneficial effect of rifampin in patients with acute staphylococcal periprosthetic joint infection treated with prosthesis retention is critically reviewed and data interpreted. Given the existing strong evidence demonstrating the benefit of rifampin, the conduction of an adequately powered RCT with appropriate definitions and interventions would probably not comply with ethical standards.

show abstract

Rifabutin Use in Staphylococcus Biofilm Infections: A Case Series

Cited by 11 publications

References 23 publications

A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections

A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections

Liposomes as a Nanoplatform to Improve the Delivery of Antibiotics into Staphylococcus aureus Biofilms

Controversy about the Role of Rifampin in Biofilm Infections: Is It Justified?

Contact Info

Product

Resources

About